论文部分内容阅读
欧洲药品评审局的专利药品委员会（CPMP）已推荐批准了福米韦生（fomivirsen,Isis和CIBAVision公司；Vitraven）。本品为一种反义制剂，适用于治疗AIDS病人的巨细胞病毒（CMV）视网膜炎。本品将用于局部治疗新近确诊的或对其它疗法无效或其它疗法不适用的晚期CMV视网膜炎。本品
The European Medicines Agency’s Patent Medicines Council (CPMP) has recommended the approval of fomivirsen (Isis and CIBAVision; Vitraven). This product is an antisense agent, suitable for treating cytomegalovirus (CMV) retinitis in AIDS patients. This product will be used for topical treatment of newly diagnosed or with other therapies invalid or other therapies do not apply advanced CMV retinitis. This product